Dr. Philip McMillan,  John McMillan

Something has shifted in the rhythm of public health news. Open any headline aggregator over the past month and the litany reads like the table of contents of a virology textbook. Ebola in the Democratic Republic of Congo. Nipah virus in India. Bird flu spreading through dairy herds. Hantavirus warnings across the American Southwest. Norovirus tearing through another cruise ship. One pathogen is conspicuously missing from the list of named threats, even though it never actually left.

So what is actually unfolding, and how worried should anyone paying attention be?

The Africa CDC announcement on 15 May 2026 confirmed a regional coordination meeting for an Ebola outbreak in the DRC, with 246 suspected cases and 65 deaths logged. Public health teams were still identifying the strain, with the more severe Zaire variant being one possibility. The numbers carry real human cost, particularly for health workers and family carers, who face the highest contact risk. Ebola spreads through body fluids from visibly ill patients, and even bodies after death remain infectious. Early intervention saves lives, and in any well-resourced system, mortality should be lower than in remote rural settings.

But Ebola, for all its lethality, is a poor candidate for a global pandemic. The reasons are structural rather than political.

What It Actually Takes to Make a Pandemic

A common assumption holds that a deadly virus equals a pandemic threat. The science says the opposite. A pandemic is built from transmissibility, not severity. The pathogens that go global share a recognisable profile. They infect humans with biological ease. They spread between people through routes that defy easy quarantine, with respiratory transmission being the most dangerous of all. They are shed in high volumes before the infected person feels unwell. They cause early symptoms so mild that the infection moves through schools, transport hubs, and workplaces while the immune system is still catching up. They emerge into a population with little or no pre-existing immunity. And they exploit a connected world of dense travel networks, faster than any new vaccine or therapy can be developed.

Severity is closer to a containment feature than a pandemic accelerator. A virus that kills its host quickly burns out its own chain of transmission. A virus that produces dramatic symptoms early gets noticed, isolated, and treated. The truly dangerous agent is the one that feels like a head cold for three days while shedding into every conversation, every elevator, every shared meal.

By this checklist, hantavirus, with its rodent reservoir and poor human-to-human spread, is unlikely to escalate. Nipah is severe but typically caught early. Norovirus is misery but not a pandemic. Bird flu remains the wildcard, warranting continuous surveillance, particularly as it adapts to mammalian hosts.

Pandemics are not annual occurrences. The last pandemic of comparable scale before COVID was the influenza wave that began in 1918, roughly a century before SARS-CoV-2 ignited in Wuhan. Smaller influenza pandemics occurred in 1957, 1968, and 2009, but none reached the population-level disruption of 1918 or 2020. Two pandemic-grade outbreaks within a single human lifetime are already unusual. Three, threatened within five years, would defy historical pattern.

The Variable Nobody Names

There is one virus missing from almost every recent press release: SARS-CoV-2 itself. The original pandemic agent has never truly receded. It has only learned to circulate quietly. Symptoms in many infections are now minimal until complications arrive weeks or months later. Population immunity from infection and vaccination remains, though waning, and the virus continues to mutate.

That quiet circulation matters for a reason most public discussion has overlooked. A population still being seeded by SARS-CoV-2 is, paradoxically, less hospitable to a new respiratory pandemic than a fully immune-naive population would be. Viral interference is a real biological effect. Interferon responses triggered by one infection can blunt the establishment of a second, particularly in respiratory tissues. A population cannot sustain a new pandemic while an epidemic is already circulating.

This is not reassurance. It is context. It explains why the current outbreak slate has so far failed to ignite, and it raises a harder question about what kind of pathogen would be capable of breaking through.

The pattern has been loud enough that one British clinician and researcher, Dr Philip McMillan, has put a name to it. “We are being pandemic groomed,” he said in a recent video address. The phrase is provocative on purpose. It invites consideration of whether the parade of named pathogens carries a psychological function as much as a biological one, conditioning the public to expect, and perhaps to accept, the next large-scale event.

Origins, the Furin Cleavage Site, and the Discipline of Hard Questions

To understand the worry behind the grooming thesis, the conversation has to return to where the last pandemic began. The furin cleavage site on the SARS-CoV-2 spike protein is a small string of amino acids positioned at the joint between the S1 and S2 subunits of the spike. Its presence makes cell entry dramatically easier. Strip it out, and the virus is unlikely to have achieved global reach.

This much is consensus virology. What remains contested is how it got there. In a 2022 conversation involving Professor Bharat Ambati and other researchers, the patent history of an almost identical amino acid sequence, filed years before the pandemic, was placed on the table. The patent itself proves nothing. Two strangers can share a fingerprint pattern by accident. But forensic minds are trained to take coincidence seriously, particularly when other evidence is also pointing toward a laboratory.

An AI-assisted likelihood assessment, drawing on the available papers and reports, ranked the possible origins of SARS-CoV-2. Natural spillover came in at moderate. A laboratory accident involving a naturally occurring bat virus came in highest, at moderate to moderately high. Engineered modification with leak sat at low to moderate. Deliberate release was rated as very low. The point is not that any single estimate is definitive. The point is that even a transparent algorithmic reading of the public record does not converge on the wet-market explanation that dominated the first eighteen months of public messaging.

A journalist who covered the pandemic offered a diagnosis that stuck. Good people, he argued, did not ask enough hard questions. They trusted the agencies designed to protect them, and that trust was weaponised, often by other well-intentioned people who had not interrogated the underlying claims themselves. The lesson is not cynicism. It is rigour.

What Comes Next

The closing concern lingers. “If there is any intention of harm, what is going to come next is going to be horrific,” McMillan warned, framing the worry around preparedness gaps rather than naming any specific threat. The implication is that current monitoring frameworks, public scepticism fatigue, and an exhausted appetite for emergency measures could leave societies poorly equipped for an event that does not behave like COVID.

There is no need to choose between paranoia and complacency. What is needed is the discipline of asking the questions that should accompany every official statement. What is the evidence base? What alternative explanations have been ruled out, and on what grounds? Who benefits from the framing, and what would change if the framing were wrong? These are the same questions a careful clinician brings to a diagnostic puzzle, weighing prior probabilities against incoming data and refusing to read a single test in isolation.

The named outbreaks of 2026 may pass without consequence. The cascade itself, and the public reflex it shapes, may be the more important story. Vigilance is not alarmism. It is, at its core, an act of citizenship.